Summary: <a href="http://www.GoodMorningGwinnett.com" rel="noopener">www.GoodMorningGwinnett.com</a> <br>Join me and 500 entrepreneurs Monday-Thursday @8am for the largest morning mastermind on the planet. Click here join us <a href="https://bit.ly/3jLMvUJ" rel="noopener">https://bit.ly/3jLMvUJ</a><br>______________________________________________<br> a highly anticipated announcement, Pfizer said on Monday a Phase 2/3 trial showed its Covid-19 vaccine was safe and generated a "robust" antibody response in children ages 5 to 11.<br><br>These are the first such results released for this age group for a US Covid-19 vaccine, and the data has not yet been peer-reviewed or published. Pfizer said it plans to submit to the US Food and Drug Administration for emergency use authorization soon.<br><br>The trial included 2,268 participants ages 5 to 11 and used a two-dose regimen of the vaccine administered 21 days apart. This trials used a 10-microgram dose -- smaller than the 30-microgram dose that has been used for those 12 and older.<br>SOURCE: <a href="http://www.GwinnettDailyPost.com" rel="noopener">www.GwinnettDailyPost.com</a>
